Cambridge, Massachusetts based neurological R&D start-up making initial public offering of 1 mil. units at anticipated price of $5 per unit. Each unit consists of three common shares and three redeemable Class A warrants. D. H. Blair, which provided first funding for firm in October 1988, is underwriting offer. Interneuron's lead compound is the glycine mediator threonine which the company hopes to develop as an orphan drug for familial spasticity ("The Pink Sheet" March 27, T&G-7).
You may also be interested in...
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
Limiting interactions to two-dimensional settings will hinder collaboration, innovation and the mentoring of younger employees, Merck & Co. CEO Kenneth Frazier says. Frazier, who will retire in June, is looking forward to returning to public service but says "politics with a capital P is not my thing."